Biogen Executive and Leadership Team

Christopher Viehbacher, the President & Chief Executive Officer at Biogen, directs the overarching corporate strategy for the development of therapies targeting neurodegenerative conditions. Overseeing the global research pipeline, the President & Chief Executive Officer ensures alignment between scientific innovation and commercial viability. This leadership role involves managing complex stakeholder relationships and driving long-term growth across international markets. By prioritizing high-impact biologics and gene-based treatments, Christopher Viehbacher shapes the future trajectory of the organization. The President & Chief Executive Officer maintains rigorous standards for operational excellence while navigating the evolving landscape of pharmaceutical manufacturing. Through consistent focus on patient outcomes, the executive secures the company position as a leader in neuroscience. This strategic vision guides the entire organization toward sustainable success in the competitive biotechnology sector.

Nicholas Colafemina, the Chief of Staff To the Chief Financial Officer. Director at Biogen, manages the financial planning and administrative operations supporting the executive finance team. Overseeing the coordination of fiscal reporting, the Chief of Staff To the Chief Financial Officer. Director ensures that financial data remains accurate and accessible for strategic decision-making. This role involves facilitating communication between the finance department and other corporate functions to maintain operational efficiency. By analyzing budgetary requirements, Nicholas Colafemina supports the allocation of capital toward high-priority research and development projects. The Chief of Staff To the Chief Financial Officer. Director monitors financial performance across global operations to identify potential risks. Through meticulous oversight, the executive contributes to the overall financial stability of the organization. This leadership role ensures that fiscal strategies align with the long-term goals of the company.

Berta Benevento, the Deputy Chief Financial Officer at Biogen, directs the financial accounting and reporting processes that underpin the company global operations. Overseeing the internal audit and compliance functions, the Deputy Chief Financial Officer ensures that all financial activities adhere to international regulatory standards. This role involves managing the capital structure and liquidity requirements to support ongoing investment in neuroscience research. By providing detailed financial analysis, Berta Benevento assists the executive team in evaluating the profitability of new therapeutic programs. The Deputy Chief Financial Officer coordinates with regional finance leads to ensure consistency in reporting across all markets. Through rigorous financial oversight, the executive maintains the fiscal health of the organization. This leadership position supports the strategic expansion of the company portfolio by ensuring robust financial foundations.

Andrew McKay, the Chief Financial Officer, Biogen (North America) at Biogen, manages the financial performance and resource allocation for the North American region. Overseeing the regional budget and revenue forecasting, the Chief Financial Officer, Biogen (North America) ensures that commercial activities remain profitable and sustainable. This role involves analyzing market trends to optimize the financial impact of product launches in the United States and surrounding territories. By collaborating with commercial leadership, Andrew McKay aligns financial goals with the broader mission of delivering neurological therapies. The Chief Financial Officer, Biogen (North America) monitors regional operational costs to improve efficiency and maximize margins. Through strategic financial planning, the executive supports the growth of the company in the competitive North American market. This leadership role ensures that regional financial objectives contribute to the overall success of the global organization.

Robin Kramer, the Executive Vice President, Chief Financial Officer at Biogen, directs the global financial strategy and capital allocation for the entire organization. Overseeing the treasury, tax, and investor relations functions, the Executive Vice President, Chief Financial Officer ensures that the company maintains a strong balance sheet to fund long-term research in neurodegenerative diseases. This role involves communicating financial performance to shareholders and the board of directors to maintain market confidence. By implementing rigorous financial controls, Robin Kramer optimizes the efficiency of global operations. The Executive Vice President, Chief Financial Officer leads the development of financial models that support the commercialization of new biologics. Through strategic oversight, the executive ensures that the company remains well-positioned for future growth. This leadership position is essential for maintaining the financial integrity and strategic focus of the enterprise.

Takatsugu Den, the President & Managing Director at Biogen, directs the operational strategy and market expansion efforts within the Asia-Pacific region. Overseeing the local commercialization of therapies for multiple sclerosis and rare diseases, the President & Managing Director ensures that the company meets the specific healthcare needs of the regional population. This role involves building strong relationships with local regulatory bodies and healthcare providers to facilitate patient access to advanced treatments. By analyzing regional market dynamics, Takatsugu Den optimizes the distribution and marketing of the product portfolio. The President & Managing Director coordinates with global leadership to align regional activities with the overarching corporate mission. Through effective management of local operations, the executive drives growth and strengthens the brand presence in the region. This leadership position ensures that the company remains a key player in the global biotechnology landscape.

Wendy Chen, the Chief Marketing Officer, Clinical Quality & Manager at Biogen, architects the commercial messaging and quality assurance frameworks for neurological treatment portfolios. Overseeing clinical quality standards, the Chief Marketing Officer, Clinical Quality & Manager ensures that all marketing initiatives remain strictly compliant with regulatory requirements. This role involves bridging the gap between complex clinical data and patient-facing communications to maximize market penetration. By analyzing regional demand, Wendy Chen optimizes the distribution of therapies for multiple sclerosis and rare disorders. The Chief Marketing Officer, Clinical Quality & Manager coordinates with medical affairs teams to validate the efficacy of new product launches. Through precise management of clinical quality metrics, the executive enhances the reputation of the brand. This leadership function drives the adoption of advanced therapies across diverse healthcare systems.

Kristin Melaugh, the Chief of Staff Commercial, SYFOVRE and EMPAVELI at Biogen, manages the operational execution of commercial strategies for specific therapeutic assets. Overseeing the integration of SYFOVRE and EMPAVELI into the broader portfolio, the Chief of Staff Commercial, SYFOVRE and EMPAVELI ensures that cross-functional teams meet aggressive growth targets. This role involves streamlining internal processes to support the rapid commercialization of gene-based therapies. By coordinating with sales and marketing departments, Kristin Melaugh facilitates the efficient delivery of treatments to patients. The Chief of Staff Commercial, SYFOVRE and EMPAVELI monitors performance metrics to identify opportunities for market expansion. Through rigorous oversight of commercial workflows, the executive supports the achievement of revenue objectives. This leadership position maintains the focus on delivering high-value solutions for rare neurological disorders.

Krystin Hein, the Chief of Staff Strategy, Medical Affairs Rare Disease & Neuropsychiatry Operations Lead (US) at Biogen, directs the strategic planning for medical affairs and neuropsychiatry operations within the North American market. Overseeing the operational infrastructure for rare disease programs, the Chief of Staff Strategy, Medical Affairs Rare Disease & Neuropsychiatry Operations Lead (US) ensures that clinical insights inform the development of new therapies. This role involves managing complex operational challenges to improve patient access to specialized treatments. By aligning medical affairs with corporate strategy, Krystin Hein drives the successful implementation of research initiatives. The Chief of Staff Strategy, Medical Affairs Rare Disease & Neuropsychiatry Operations Lead (US) coordinates with internal stakeholders to optimize resource allocation. Through effective leadership, the executive strengthens the company presence in the neuropsychiatry sector.

Michael Parini, the Chief Legal Officer at Biogen, directs the legal and compliance frameworks that govern the development and commercialization of neurological therapies. Overseeing intellectual property protection, the Chief Legal Officer ensures that the company research innovations remain secure in a competitive global market. This role involves managing complex regulatory challenges and litigation risks to protect the interests of the organization. By providing legal guidance on corporate governance, Michael Parini supports the ethical conduct of all business operations. The Chief Legal Officer coordinates with the board of directors to ensure compliance with international laws and industry standards. Through proactive legal strategy, the executive mitigates risks associated with the launch of new gene-based treatments. This leadership position maintains the legal integrity of the company while facilitating the pursuit of its mission to treat serious neurological disorders.